ood morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies hovering over the relatively quiet Pharmalot campus. Our short person successfully arrived at the local schoolhouse for another day of learning. Our official mascots are happily snoozing by our feet. And the coffee kettle is brewing another delicious cup of stimulation — pecan pie is the flavor today. All that is left for us to do is dig in and pass along some items of interest. Speaking of which, here are some tidbits. Have a lovely day and please keep in touch …

Merck (MRK) is not seeking regulatory approval for a type of cholesterol-lowering medicine that has vexed other drug makers. The unsurprising decision comes after a large study found its drug cut the risk of heart attack and death by a modest 9 percent, and caused a buildup of the drug in fat tissue. Known as a CETP inhibitor, anacetrapib is supposed to raise HDL, or good cholesterol, while lowering LDL, or bad cholesterol. Other CETP drugs have flopped.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • While DrugChannels observers there may be an incentive to ‘buy early,’ the law is potentially a disincentive to large price hikes – and the manufacturers have no incentive to abet this kind of ‘channel stuffing’ when delay would earn them more for less. “Just sayin’ ” ….

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.